预约演示
更新于：2025-09-19
Dapirolizumab pegol
更新于：2025-09-19
概要
基本信息
在研机构 |
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 58046H
来源: *****
Sequence Code 58056L
来源: *****
关联
11
项与 Dapirolizumab pegol 相关的临床试验NCT06617325
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
开始日期2024-11-21 |
申办/合作机构 |
NCT04976322
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus
The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.
开始日期2021-07-27 |
申办/合作机构 |
EUCTR2019-001967-58-FR
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active-Reference (Ocrelizumab), Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous Dapirolizumab Pegol (BIIB133) in Relapsing Multiple Sclerosis - Efficacy and Safety Study of Dapirolizumab pegol (BIIB133) in Participants with RMS
开始日期2020-11-20 |
申办/合作机构 |
100 项与 Dapirolizumab pegol 相关的临床结果
登录后查看更多信息
100 项与 Dapirolizumab pegol 相关的转化医学
登录后查看更多信息
100 项与 Dapirolizumab pegol 相关的专利（医药）
登录后查看更多信息
506
项与 Dapirolizumab pegol 相关的文献（医药）2025-11-01·ENVIRONMENTAL POLLUTION
Study on the residual dynamics of diazepam in freshwater fish of Zhejiang, China and its implications for human health
Article
作者: Cui, Jing ; Lu, Chenze ; Hong, Min ; Fang, Jiehong ; Jiang, Han ; Zhong, Shihuan ; Wang, Jing
This study provides an in-depth evaluation of diazepam (DZP) and its metabolites in freshwater fish from Zhejiang Province, China, during 2020-2024, with a focus on contamination trends, source attribution, bioaccumulation behavior, and potential human health risks. The results reveal a significant upward trend in DZP detection, rising from 0.33 % to 4.67 %, accompanied by a 75 % increase in mean residue concentrations-from 2.31 ± 1.26 μg/kg to 4.04 ± 7.65 μg/kg-and a maximum concentration reaching 76.04 μg/kg. Recreational fishing areas exhibited the most severe contamination, with crucian carp identified as the most heavily affected species. Among DZP metabolites, nordiazepam (NZP) exhibited stable detection rates (1.20-1.37 %), while oxazepam and temazepam were rarely detected, suggesting selective metabolic pathways. Source analysis identified bait as the dominant contributor, with DZP levels reaching up to 1.10 × 105 μg/kg. Crucian carp exhibited the highest bioaccumulation factor (BCF = 1238.60), reinforcing their heightened susceptibility. Molecular docking analyses revealed species-specific binding affinities of DZP and NZP to fish GABA receptors, providing mechanistic insight into observed residue patterns. Health risk assessments indicated low average dietary exposure for adults, whereas under extreme exposure scenarios, hazard quotients (HQ) for children approached the threshold of concern (HQ = 0.49). These findings underscore the urgent need for strengthened regulation of bait quality and contamination control in recreational fishing areas to mitigate future food safety risks.
2025-11-01·NEUROPHARMACOLOGY
Increased NMDAR activity and GluN2A-NMDAR silent synapse expansion induced by chronic benzodiazepine treatment
Article
作者: Chapman, Caitlyn A ; Povysheva, Nadya ; Jacob, Tija C ; Johnson, Jon W
Benzodiazepines (BZDs) are critical sedative, anticonvulsant, and anxiolytic drugs that potentiate inhibitory GABAergic neurotransmission. However, clinical utility is hampered by drug tolerance and a hyperexcitable withdrawal syndrome characterized by neuronal excitation/inhibition (E/I) imbalance. Although enhanced excitation is implicated in BZD tolerance, the homeostatic changes to glutamatergic receptors remain undefined. Here, we report the impact of chronic (7-day) BZD treatment on excitatory synapse and NMDA receptor (NMDAR) function, expression, and subcellular localization in cortical neurons. Chronic treatment with the BZD diazepam (DZP) resulted in an increase in NMDAR-mediated miniature excitatory postsynaptic currents (mEPSCs). Confocal imaging studies revealed a DZP-induced enrichment of GluN2B-containing NMDARs at functional synapses (expressing AMPA receptors, AMPARs) while GluN2B subunit expression was otherwise unaltered. Conversely, localization of GluN2A-containing NMDARs (GluN2A-NMDARs) to functional synapses was unchanged, while GluN2A-NMDAR total protein levels and surface accumulation were enhanced. Intriguingly, we demonstrate for the first time the BZD-induced enrichment and expansion of GluN2A-NMDAR coverage at silent (AMPAR-lacking) synapses. Finally, biochemical fractionation analysis of the translation elongation protein eEF2, known to control E/I balance, detected lower levels of deactivated, phosphorylated eEF2 in the synaptic fraction of DZP-treated neurons, indicative of enhanced local translation. Collectively, our findings suggest that chronic BZD treatment triggers compensatory mechanisms which 1) enhance NMDAR function via increased GluN2B-NMDARs at functional synapses, and 2) promote the expression, surface localization, and accumulation of GluN2A-NMDARs at silent synapses, augmenting the potential for further synaptic plasticity.
2025-08-01·NEUROSCIENCE
Combined aerobic and resistance exercise was able to reduce inflammatory cytokines and oxidative markers in the hippocampus of Wistar rats subjected to an epileptic seizure protocol
Article
作者: Rosa, Gabriel de Lima ; Coitinho, Adriana Simon ; Siqueira, Ionara Rodrigues ; de Lima, Amanda Muliterno Domingues Lourenço ; Bitello Nunes, Silvia Elisandra ; Sulzbach, Ana Carolina ; da Rosa Araujo, Alex Sander ; Padilha, Rafael Bremm ; Türck, Patrick ; Guzzo, Edson Fernando Muller
The practice of physical exercise by people with epilepsy still faces resistance, despite evidence supporting its benefits. However, the effects of combining exercise with anti-inflammatory drugs remain unclear. This study evaluated the impact of physical exercise, alone or with prednisolone, on seizure parameters and markers of inflammation and oxidative stress in the cortex and hippocampus of Wistar rats subjected to chemically induced seizures. A kindling model using pentylenetetrazole (PTZ) was applied over 14 alternate days. Animals were divided into four groups: sedentary (SED), diazepam (DZP), exercise + prednisolone (EP), and exercise + saline (ES). Exercise groups performed alternating aerobic and resistance training during the protocol. Behavioral assessments included seizure severity (Racine scale), latency, and occurrence. Tissue analyses measured cytokines (TNF-α, IL-1β, IL-10) and oxidative markers (ROS, nitrites, sulfhydryl content, TBARS). No significant behavioral differences were found between the exercise and sedentary groups. As expected, DZP reduced seizure severity, latency, and occurrence. The EP group showed reduced hippocampal TNF-α compared to DZP (p = 0.029), and lower ROS (p = 0.030), nitrites (p < 0.01), and sulfhydryl content (p = 0.023). Conversely, ES animals had higher IL-1β levels in cortex and hippocampus versus DZP and EP, suggesting a pro-inflammatory effect of exercise alone. TBARS levels were unchanged. These findings indicate that while exercise alone did not alter seizure outcomes, its combination with prednisolone yielded anti-inflammatory and antioxidant effects in the hippocampus. This suggests that combined interventions may modulate neuroinflammation and oxidative stress, offering potential non-pharmacological strategies to support epilepsy treatment.
71
项与 Dapirolizumab pegol 相关的新闻（医药）2025-09-09
Pictured: Biogen’s signage at its headquarters in Massachusetts
iStock,
JHVEPhoto
With two late-stage programs set to read out in the next 48 months, Biogen is translating its wealth of experience in multiple sclerosis to lupus—developing a pipeline BMO Capital Markets analysts called “thoughtful.”
With its storied multiple sclerosis franchise
under increasing pressure
from declining sales, Biogen’s other programs are stepping into the spotlight—including one where the biotech is leveraging that deep well of immunological experience. Last week, the Cambridge, Mass.–based company held an investor call highlighting its lupus portfolio, helmed by two late-stage assets representing a multi-faceted approach to the autoimmune disease.
The first of these, dapirolizumab pegol, being developed in collaboration with UCB, is currently in a second Phase III study with confirmatory data expected in late 2027 or 2028. Meanwhile, litifilimab is involved in three ongoing Phase III studies, all reading out in the next couple of years.
“We’re at this inflection point now,” Diana Gallagher, senior vice president of the Multiple Sclerosis and Immunology Disease Unit and Alzheimer’s and Dementia Disease Unit at Biogen, told
BioSpace
prior to the investor presentation. “We’ve been working in lupus for almost the whole decade that I’ve been here, but really are now at this really exciting point.”
Diana Gallagher
When asked if the lupus franchise is taking the place of MS in terms of clinical development, Gallagher said, “hopefully it’s a ‘yes, and’ kind of answer.
“I still have this sort of really interesting MS portfolio,” she continued. “But yes, I do think that there is intention at Biogen to have this exciting neurology pipeline, an immunology pipeline and a rare disease pipeline. You’ll see the three really pillars of our strategy.”
At least one analyst firm reacted positively to the peek under Biogen’s immunological hood.
“Biogen lupus pipeline event highlights thoughtful approach to develop assets targeting a diease [sic] with high unmet need,” BMO Capital Markets wrote Sept. 3 in a note to investors. Zooming out on the company, the group added, “With commercial stories like Leqembi, Skyclarys, and Spinraza taking more priority, we are starting to get the feeling that Biogen’s pipeline may be underappreciated, a point emphasized by today’s presentation.”
The Lupus Landscape
A complex autoimmune disease affecting multiple organ systems and disproportionately afflicting women and people of color, lupus has long proven difficult to treat.
In the past 50 years, there have only been two drugs approved for lupus, Gallagher said: GSK’s Belimumab, approved in 2011, and
AstraZeneca’s Saphnelo
, greenlit in 2021. “So it’s really been quite quiet.”
In terms of barriers to therapeutic progress, Gallagher pointed to potential sociodemographic reasons and a complicated biology. “People felt like they couldn’t unravel it. They’re like, oh, there’s so much redundancy, we don’t know what targets to go after.” Adding to these challenges, she said, have been “a lot of failed trials, which makes people shy away, because they’re like, oh, nothing works.”
However, she said, the space is “definitely making great strides.”
Biogen’s Approach
While tackling lupus is a tall order, Gallagher said Biogen “feel[s] like we understand the complexity of immunology and having to have a multi-faceted approach.”
And while lupus and MS are certainly not the same, Gallagher pointed to several similarities. Both diseases are immunologically based, predominantly affect young women—
approximately 90%
of lupus diagnoses are in female patients—and have a relapsing/remitting course.
Biogen was one of the first companies “to go into MS and uncouple all that and bring multiple drugs to market,” Gallagher said. “We see [lupus] as another sort of area that we can spend that time that it takes—and we’ve been at it for a couple decades now—to really unravel this and bring a multi-faceted approach for these patients who really have been waiting a long time to have adequate therapy.”
As for this multi-faceted approach, dapirolizumab pegol (DZP), a humanized Fc-free polyethylene glycol (PEG)-conjugated antigen-binding fragment, is targeting SLE. DZP inhibits the signaling of CD40L, a key target to disrupt CD40 signaling and interrupt the immunological cascade in SLE, according to Biogen’s
investor presentation
on Wednesday.
Biogen and UCB claimed a
Phase III win
for DZP last September in what Stifel analysts at the time called a “positive surprise.” This followed a
Phase II failure
for the drug in 2018 when it was unable to demonstrate a significant dose response at 24 weeks. Despite the missed endpoint, the partners pushed forward, betting on what they flagged as “consistent and potentially meaningful improvements” across “majority of clinical endpoints.” So far, this bet appears to have paid off.
A second Phase III candidate, litifilimab, a humanized IgG1 monoclonal antibody targeting BDCA2, is in development for both SLE and cutaneous lupus erythematosus (CLE). The BDCA2 receptor is predominantly expressed on a subset of immune cells called plasmacytoid dendritic cells (pDCs). When binding to BDCA2, litifilimab has demonstrated the ability to reduce production of pro-inflammatory molecules by pDCs, including type-I interferon, cytokines and chemokines, pro-inflammatory mediators that are thought to play a significant role in both SLE and CLE,
according to Biogen
. The first Phase III data for litifilimab, from two trials in SLE, are expected by the end of 2026, Gallagher said, while Phase III CLE data should follow in 2027.
Finally, Biogen’s 2024
acquisition of Human Immunology Biosciences
(HI-Bio) brought into the fold felzartamab, an investigational antibody targeting CD38. Biogen is studying felzartamab in a range of disease areas, including lupus nephritis, where it’s currently in a Phase Ib trial. Gallagher hopes to see topline data from this trial next year.
“So next year, for sure, a lot of cards flipping,” she said. “It’s exciting.”
临床3期免疫疗法上市批准并购临床2期
2025-06-12
·药明康德
优于标准治疗！渤健与UCB创新疗法3期试验结果积极渤健（Biogen）与优时比（UCB）今日公布了dapirolizumab pegol（DZP）在3期PHOENYCS GO研究的详细结果。这是一款与聚乙二醇（PEG）偶联、不含Fc片段、CD40配体靶向的人源化抗原结合片段（Fab’），用于治疗中至重度系统性红斑狼疮（SLE）患者。在该研究中，DZP在第48周显著改善了患者的疾病活动度，达成主要终点。此外，DZP在疲劳、疾病活动度等多个临床指标上亦表现出积极疗效。目前，一项旨在验证PHOENYCS GO研究结果的第二项3期临床试验正在进行中。在该研究中，DZP在多项疲劳相关的患者报告指标上均优于标准治疗（SOC）组。在FACIT疲劳评分方面，DZP组较基线改善8.9分，而SOC组为5.2分（p=0.0024）。在新开发用于反映SLE患者疲劳体验的FATIGUE-PRO疲劳量表中，在身体疲劳方面，DZP组与SOC组差值为7.6分，DZP组在心理与认知疲劳（差值5.6分）以及易疲劳性（差值7.8分）上亦均优于SOC组（p<0.05）。此外，在第48周，DZP组达到低疾病活动状态（LLDAS）和疾病缓解（DORIS）的比例显著高于SOC组，分别为40.9%对19.6%（p<0.0001）和19.2%对8.4%（p=0.0056），表明其在调控疾病活动和减少糖皮质激素使用方面具有潜在价值。100%疾病控制率！潜在“first-in-class”抗体亮眼试验结果公布BioInvent International今日公布其抗TNFR2抗体BI-1808单药治疗皮肤T细胞淋巴瘤（CTCL）临床2a期剂量扩展研究的最新积极数据。截至2025年5月15日，在九名可评估的CTCL患者中，疾病控制率（DCR）达到了100%。其中，一名患者实现完全缓解（CR），三名为部分缓解（PR），五名为疾病稳定（SD）。此外，在两名可评估的外周T细胞淋巴瘤（PTCL）患者中，一名达到部分缓解，另一名为疾病稳定。整体数据显示，BI-1808单药在T细胞淋巴瘤中展现出良好的抗肿瘤活性和强效的免疫介导效应。BI-1808也表现良好的安全性，所有治疗相关不良事件均为轻度或中度（1-2级），未观察到3级或以上的不良事件。该研究仍在持续招募患者，并将在后续进入剂量优化阶段。BI-1808是BioInvent肿瘤相关调节性T细胞（Treg）靶向项目的一部分，该疗法通过抑制肿瘤微环境中高度表达的TNFR2，有望阻断Treg介导的免疫抑制，从而促进抗肿瘤免疫反应。这一潜在“first-in-class”候选药物目前正被开发用于实体瘤和血液肿瘤的治疗，并已在单药和联合PD-1抑制剂pembrolizumab治疗的临床研究中表现出初步疗效和良好的安全性。12.5亿美元！BioNTech再布局mRNA领域BioNTech与CureVac今日联合宣布，双方已签署最终协议，BioNTech以总计约12.5亿美元收购CureVac。CureVac是一家处于临床阶段的生物技术公司，专注于开发基于mRNA的创新肿瘤和传染病治疗药物。此次交易将整合双方在技术上的互补优势，进一步加强BioNTech在全球mRNA领域的布局。通过本次收购，BioNTech将进一步加强其在mRNA癌症免疫疗法方面的研发、生产及商业化能力。此次战略交易将补充BioNTech在mRNA序列设计、递送系统和制造技术方面的既有专长，并有助于推进其两项泛肿瘤项目、多个mRNA癌症免疫疗法候选药物，以及双特异性抗体BNT327（靶向PD-L1和VEGF-A）的开发。参考资料：[1] Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity. Retrieved from https://www.globenewswire.com/news-release/2025/06/12/3098034/0/en/Dapirolizumab-Pegol-Phase-3-Data-in-SLE-Presented-at-the-Annual-European-Congress-of-Rheumatology-EULAR-Show-Improvement-in-Fatigue-and-Reduction-in-Disease-Activity.html[2] BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025. Retrieved June 12, 2025 from https://www.bioinvent.com/en/press/bioinvent-presents-promising-phase-2a-monotherapy-data-bi-1808-ctcl-eha-2025-2338950[3] BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer. Retrieved June 12, 2025 from https://investors.biontech.de/news-releases/news-release-details/biontech-announces-strategic-transaction-acquire-curevac-public免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新
信使RNA临床3期临床结果临床2期
2025-06-12
BRUSSELS, Belgium and CAMBRIDGE, MA, USA I June 12, 2025 I
UCB
(Euronext Brussels: UCB) and
Biogen Inc.
(NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO.
“Despite being a common manifestation of systemic lupus erythematosus, fatigue is a difficult-to-treat symptom that can severely impact a person’s quality of life, and remains a challenge to address,” said Ioannis Parodis, MD, PhD, Associate Professor of Rheumatology, Karolinska University Hospital, Sweden. “The results we observed in this Phase 3 study indicate that participants treated with dapirolizumab pegol have the potential to achieve consistent improvements in fatigue beyond the current standard of care.”
In an analysis of the impact of DZP on patient-reported fatigue in people with SLE participating in the PHOENYCS GO study, individuals receiving DZP in addition to standard of care (SOC) treatment demonstrated improvements across two fatigue measurements:
“Being able to address both fatigue and remission are areas of critical unmet need in lupus care, an important treatment goal is to improve the quality of life for patients as well as to reduce the long-term risk of organ damage through disease remission,” said Eric F. Morand, MBBS, Head of the Monash Health Rheumatology Unit, Monash University, Australia. “In the PHOENYCS GO study, dapirolizumab pegol has shown meaningful impact in helping patients achieve remission and low disease activity, offering the exciting possibility for improved disease control while reducing exposure to glucocorticoids. Dapirolizumab pegol has the potential to become a significant new medication for people living with SLE, as shown by the breadth of effect seen in the study and I look forward to seeing results from the second Phase 3 study.”
In an additional analysis, improvements were seen on measures of low disease activity, as measured by Low Lupus Disease Activity State (LLDAS) and disease remission, as measured by Definition of Remission in SLE (DORIS). Both measures include assessments of disease activity, in addition to a required low dose glucocorticoid intake (<7.5 mg prednisone / day in LLDAS; <5 mg prednisone / day in DORIS).
* Having met the primary endpoint, improvement of moderate-to-severe disease activity as assessed by achievement of BICLA after 48 weeks and the key secondary endpoint having a p-value = 0.1776, all subsequent secondary and tertiary endpoints are descriptive and nominal p-values are included.
The safety profile of DZP was generally favorable. The safety results were consistent with previous DZP studies and with that in study participants with SLE receiving an immunomodulator. A higher proportion of individuals receiving DZP plus SOC had treatment-emergent adverse events (TEAEs) compared to SOC alone (82.6% vs. 75.0%). The proportion of participants with serious TEAEs was 9.9% in participants receiving DZP plus SOC was lower as compared to 14.8% in those receiving SOC alone. Discontinuation of treatment or study participation due to TEAEs occurred in 4.7% (10) of participants receiving DZP plus SOC and 3.7% (4) of participants receiving SOC alone.
Participants from the PHOENYCS GO study (NCT04294667) will continue to be followed in a long-term open-label study. A second Phase 3 trial of dapirolizumab pegol, PHOENYCS FLY (
NCT06617325
) is ongoing.
About Systemic Lupus Erythematosus (SLE)
SLE is a chronic, multifactorial autoimmune disease that is caused by the activation of autoreactive T, B and antigen-presenting cells, resulting in manifestations across multiple organ systems with periods of illness or flares alternating with periods of inactivity.
1
SLE can present itself in several ways including rash, arthritis, anemia, thrombocytopenia, serositis, nephritis, seizures or psychosis.
2
SLE is associated with a greater risk of death from causes such as infection and cardiovascular disease.
An estimated 90% of people living with lupus are women; most begin to see symptoms between the ages of 15-55.
3,4,5
Individuals from populations of African, Hispanic, Asian and Native American descent are at a greater risk of earlier onset and more aggressive disease.
6,7
Pregnancy in women with SLE is high risk, with higher maternal and fetal mortality and morbidity than the general population.
8,9
About Dapirolizumab Pegol
Dapirolizumab pegol is a novel investigational humanized Fc-free polyethylene glycol (PEG)-conjugated antigen-binding (Fab’) fragment. Dapirolizumab pegol inhibits CD40L signaling which has been shown to reduce B cell activation and autoantibody production, mitigate type 1 interferon (IFN) secretion, and attenuate T cell and antigen-presenting cell (APC) activation.
10
Dapirolizumab pegol is presently in Phase 3 clinical development for the treatment of systemic lupus erythematosus (SLE) under a collaboration between UCB and Biogen.
11
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB).
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
The company routinely posts information that may be important to investors on its website at
www.biogen.com
. Follow us on social media –
Facebook
,
LinkedIn
,
X
,
YouTube
.
References:
SOURCE:
Biogen
临床3期临床结果
100 项与 Dapirolizumab pegol 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 系统性红斑狼疮 | 临床3期 | 美国 | 2020-08-12 | |
| 系统性红斑狼疮 | 临床3期 | 阿根廷 | 2020-08-12 | |
| 系统性红斑狼疮 | 临床3期 | 澳大利亚 | 2020-08-12 | |
| 系统性红斑狼疮 | 临床3期 | 奥地利 | 2020-08-12 | |
| 系统性红斑狼疮 | 临床3期 | 比利时 | 2020-08-12 | |
| 系统性红斑狼疮 | 临床3期 | 保加利亚 | 2020-08-12 | |
| 系统性红斑狼疮 | 临床3期 | 加拿大 | 2020-08-12 | |
| 系统性红斑狼疮 | 临床3期 | 智利 | 2020-08-12 | |
| 系统性红斑狼疮 | 临床3期 | 哥伦比亚 | 2020-08-12 | |
| 系统性红斑狼疮 | 临床3期 | 捷克 | 2020-08-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | 315 | Dapirolizumab pegol+Standard of Care | 製齋選餘顧醖廠糧蓋餘(積積窪窪壓觸鏇膚顧壓) = 蓋獵夢壓繭製簾壓簾壓 糧範膚顧窪鏇製膚廠願 (簾選製鹽壓憲繭鹹獵鏇 ) 更多 | 积极 | 2025-06-11 | ||
Placebo+Standard of Care | 製齋選餘顧醖廠糧蓋餘(積積窪窪壓觸鏇膚顧壓) = 夢網襯鏇選鑰鏇鹹淵鹽 糧範膚顧窪鏇製膚廠願 (簾選製鹽壓憲繭鹹獵鏇 ) 更多 | ||||||
临床3期 | 315 | Dapirolizumab pegol + Standard of Care | 壓齋糧繭廠顧顧繭淵鹹(廠衊糧夢淵鹽壓鹽範鏇) = 鑰齋選觸鏇膚醖艱糧範 蓋構願鏇夢廠顧醖繭顧 (觸廠齋觸糧鑰簾鹽憲糧 ) 更多 | 积极 | 2025-06-11 | ||
Placebo + Standard of Care | 壓齋糧繭廠顧顧繭淵鹹(廠衊糧夢淵鹽壓鹽範鏇) = 範蓋鏇夢餘範顧願網選 蓋構願鏇夢廠顧醖繭顧 (觸廠齋觸糧鑰簾鹽憲糧 ) 更多 | ||||||
临床3期 | 321 | placebo (PBO) (PBO+SOC) | 顧糧願願糧襯構獵襯餘 = 構網鑰夢鹽鏇醖鬱獵醖 淵窪夢鑰繭糧遞網餘獵 (鬱醖簾繭夢製夢繭顧製, 範觸艱製觸壓願淵膚觸 ~ 艱遞網蓋醖遞醖廠窪壓) 更多 | - | 2025-04-24 | ||
(DZP+SOC) | 顧糧願願糧襯構獵襯餘 = 膚壓網積簾膚積鏇鹹鹽 淵窪夢鑰繭糧遞網餘獵 (鬱醖簾繭夢製夢繭顧製, 築簾膚鹹淵繭窪齋選獵 ~ 淵憲鑰膚顧鹽觸鹽壓醖) 更多 | ||||||
临床3期 | 315 | Dapirolizumab pegol + SOC | 襯遞鏇襯鏇網鹽鏇艱獵(膚鹽網鏇鹽築鑰憲獵築) = 憲壓艱網窪範憲鬱顧壓 餘鏇獵齋齋壓淵鹹築製 (觸製鑰繭膚餘夢獵築淵 ) 达到 更多 | 积极 | 2024-10-24 | ||
Placebo+SOC | 襯遞鏇襯鏇網鹽鏇艱獵(膚鹽網鏇鹽築鑰憲獵築) = 積襯範積鑰簾範範選獵 餘鏇獵齋齋壓淵鹹築製 (觸製鑰繭膚餘夢獵築淵 ) 达到 更多 | ||||||
临床3期 | 321 | 廠憲餘獵壓鬱鑰夢築廠(遞範積襯鬱夢蓋鑰顧夢) = The trial achieved its primary endpoint. 衊窪醖鑰選糧膚鹽壓觸 (鏇網簾襯廠廠艱繭餘膚 ) 达到 更多 | 积极 | 2024-09-24 | |||
临床2期 | - | PBO+SOC | 蓋選廠襯選醖鏇觸獵餘(壓範鹽願衊網願襯膚構) = 選襯顧鹹鬱壓窪製觸積 簾網糧窪積鹹蓋齋壓夢 (廠糧積窪鹽構積壓艱憲 ) 未达到 更多 | 不佳 | 2021-11-03 | ||
dapirolizumab pegol 6 mg/kg+SOC | 蓋選廠襯選醖鏇觸獵餘(壓範鹽願衊網願襯膚構) = 夢積淵醖範壓積範鹽獵 簾網糧窪積鹹蓋齋壓夢 (廠糧積窪鹽構積壓艱憲 ) 未达到 更多 | ||||||
临床1期 | 24 | 憲鏇鬱顧鹹構夢範選鑰(襯遞憲鏇廠蓋獵淵窪鹹) = 夢糧襯獵糧構廠膚夢顧 窪願艱廠鏇餘選齋遞顧 (膚鹹糧繭糧願遞壓觸簾 ) 更多 | 积极 | 2017-11-01 | |||
Placebo | 憲鏇鬱顧鹹構夢範選鑰(衊鑰醖築積糧襯願衊餘) = 鹹鑰遞築廠醖蓋簾網積 夢範遞膚窪範夢憲廠願 (壓餘鏇廠窪蓋齋範網顧 ) 更多 | ||||||
临床1期 | 28 | (healthy individuals) | 選鬱網衊窪構廠鏇廠顧(膚夢餘鬱簾糧製糧遞簾) = 網齋鏇憲齋襯襯齋積顧 膚獵選鏇鏇齋糧鏇積願 (艱膚餘醖淵築築構築簾 ) | 积极 | 2015-03-16 | ||
Placebo (healthy individuals) | - |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用